Sources: Chinese regulators have slowed approvals of mergers by US companies, asking some to make products that they sell in other countries available in China
The U.S. encouraged China to set up a robust antitrust regime. Now, Beijing is holding back its required green light for mergers …
Context & Ripple Effects
This is a familiar lever reappearing under new conditions. As early as January 2021, Beijing was already slowing regulatory clearance of US tech acquisitions as tensions rose — today's reporting shows the tactic has matured from mere delay into an explicit ask: merge approval in exchange for bringing foreign-sold products into China.
It sits alongside other recent instances of Beijing conditioning access on compliance rather than publishing formal rules — [[a:886482|Apple and Alibaba's AI rollout stalled at the Cyberspace Administration despite hundreds of approved domestic models]], and an undocumented requirement that chipmakers use majority-domestic equipment when adding capacity. Approval itself is becoming the product.
First-order effects
- US companies with pending mergers now face open-ended closing timelines in China, and some must commit to launching products they currently sell only abroad if they want SAMR's green light.
- Deal teams at US acquirers have to treat Chinese antitrust sign-off not as a rubber stamp but as a negotiation over portfolio and pricing commitments made before the deal can legally close globally.
Second-order effects
- US M&A advisers will begin pricing China-approval risk into deal structures and timing — either excluding Chinese-relevant assets, pre-negotiating product commitments, or steering combinations around jurisdictions where Beijing holds veto power.
- The asymmetry cuts both ways against Washington's own toolkit: the US has weighed blocking American investment in Alibaba and Tencent (a January 2021 debate) and proposed barring data-heavy Chinese firms from US listings, so each side's approval machinery becomes retaliation material for the other's next move.
Third-order effects
- If the pattern holds, cross-border M&A splits into two cleared lanes — deals that matter to Beijing get negotiated through regulators, deals that don't simply route around China — shrinking the pool of genuinely global corporate combinations.
- Regulatory approval hardens into a standing instrument of market-access policy: what used to be negotiated in trade rounds gets extracted one merger at a time, with no treaty trail and no published rule to contest.
The trend: Market access is increasingly granted or withheld through individual regulatory acts — antitrust clearances, AI model approvals, procurement quotas — making governance itself the trade barrier.